The other group at the highest risk when it comes to RSV is children under age five, and specifically infants—especially ...

The CDC recommends a single dose of any FDA-approved respiratory syncytial virus (RSV) vaccine for all adults ages 75 years ...

Current guidelines recommend that pregnant people receive a vaccine against respiratory syncytial virus (RSV) -- which typically causes mild, cold-like symptoms in most adults but can be deadly for ...

In three months, the distribution of RSV vaccines will begin in the Americas, according to a PAHO announcement.

For adults aged 60 years or older, RSV vaccination is effective for preventing associated hospitalizations and ED encounters.

Current guidelines recommend that pregnant people receive a vaccine against respiratory syncytial virus (RSV)-;which typically causes mild, cold-like symptoms in most adults but can be deadly for ...

Infants are among the most susceptible to respiratory complications from respiratory syncytial virus, or RSV. While they can ...

Respiratory syncytial virus and influenza activity are on the rise in parts of the country, particularly among young children, according to the CDC's latest respiratory virus updates. Overall, the ...

The seasonal COVID-19 spike, combined with rising cases of seasonal flu and RSV, brings what has been called a “tripledemic.” ...

Coughing, sneezing, and high temperature are common signs of a cold. While these may look harmless, they can also be symptoms ...

The microbiologic confirmation of RSV infection is based on detecting the virus in a sample of wash or a swab obtained from the nasopharyngeal cavity. A variety of laboratory techniques can be ...

The world's first bivalent mRNA vaccine candidate against respiratory syncytial virus, or RSV, kicked off Phase I clinical ...